Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M

Shattuck Labs, Inc.

Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.
Positive Phase 1A/B SL-172154 data in HR-MDS and TP53m AML; completed initial enrollment for expansion cohorts.
Completed Phase 1B SL-172154 + PLD trial in PROC with positive interim data; all mid-2024 updates expected.
Strategic collaboration with Ono Pharma for autoimmune targets; up to $227M in milestones plus tiered royalties.
Completed $50M public offering in Q4 2023; cash runway extended into 2026 beyond Phase 1 readouts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Shattuck Labs, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent business highlights.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.